Avesta76

Avesta76

  Avesta76 is focused on a target that has the potential to treat every type of tumor. Market: Avesta76's therapies will address the need for safe and effective treatments across multiple cancers. This is a market with 17 million annual diagnoses, 10 million deaths,...

Capacity Bio is developing the most comprehensive and advanced mitophagy therapeutics and development platform for the purpose of restoring mitochondria quality control in disease. Market:Their lead focus is neurodegeneration and muscular disorders, including...
CDR3 Therapeutics, Inc.

CDR3 Therapeutics, Inc.

CDR3 develops stem cell-based immunotherapies to cure HPV-related cancers using chimeric antigen receptors or chronic viral infections using T cell receptors. Market: Today, we lack cures for most virus-related cancers and chronic viral infections, especially from...
Forcyte Biotechnologies, Inc.

Forcyte Biotechnologies, Inc.

Forcyte Biotechnologies, Inc. is the first company aiming to tackle diseases of cell mechanobiology by directly screening contractile cell force in an automation-friendly & high-throughput format. Market: Forcyte Biotechnologies, Inc. provides predictive disease...
ImmunoVec

ImmunoVec

ImmunoVec is developing gene therapy treatments for life-threatening hematopoietic diseases. Market:There are over 300 life-threatening primary immune deficiencies for which there are limited treatment options currently available. Technology:ImmunoVec has developed a...